Asterias Biotherapeutics Inc (AST) was Initiated by Rodman & Renshaw to “Buy” and the brokerage firm has set the Price Target at $12. Rodman & Renshaw advised their investors in a research report released on Apr 25, 2016.
Asterias Biotherapeutics Inc closed down -0.05 points or -1.17% at $4.21 with 27,142 shares getting traded on Friday. Post opening the session at $4.25, the shares hit an intraday low of $4.18 and an intraday high of $4.3 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Sep 16, 2015, Jane Lebkowski (President of R&D) sold 4,912 shares at $6.00 per share price. According to the SEC, on Sep 16, 2015, Edward Wirth (Chief Medical Officer) sold 2,880 shares at $6.00 per share price. On Sep 16, 2015, Katharine E. Spink (VP and Chief Operating Officer) sold 3,760 shares at $6.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Asterias Biotherapeutics Inc. is a biotechnology company. The Company is focused in the field of regenerative medicine. It has three clinical stage product candidates: AST-OPC1 indicated for spinal cord injuries; AST-VAC2 indicated for lung cancer and AST-VAC1 indicated for prostate cancer and acute myelogenous leukemia. The Company’s product development is focused primarily on AST-OPC1 and AST-VAC2. The Company’s lead therapeutic program focuses on the development of AST-OPC1 for spinal cord injury. AST-OPC1 product consists of glial progenitor cells which are cells that become glial cells after injection. AST-VAC1 is an autologous product (using cells that come from the treated patient) consisting of mature antigen-presenting dendritic cells pulsed with ribonucleic acid (RNA) for the protein component of human telomerase (hTERT) and a portion of a lysosomal targeting signal (LAMP).